Andere Sprachen Telix Pharmaceuticals Limited

Aktien

A2H7JK

AU000000TLX2

TLX

Markt geschlossen - Australian S.E. Andere Börsenplätze 08:10:55 23.04.2024			% 5 Tage	% 1. Jan.
14.3 ^AUD	+1.42%		+12.33%	+41.87%

17.04.	Telix Pharmaceuticals Limited bekräftigt Umsatzprognose für das Jahr 2024	CI
17.04.	Telix Pharmaceuticals meldet fast $115 Millionen Umsatz in Q1	MT

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Telix - Notice of Annual General Meeting 2024	22.04.
Q1 2024 Revenue and Business Update	17.04.
Telix Pharmaceuticals Limited Reports Unaudited Revenue Results for the First Quarter Ended 31 March 2024	17.04.
Telix Pharmaceuticals Limited Reaffirms Revenue Guidance for the Year 2024	17.04.
Telix Pharmaceuticals Logs Nearly $115 Million Revenue in Q1	17.04.
Telix Pharmaceuticals Secures US FDA Fast-Track Designation for Brain Cancer Imaging Product	16.04.
TLX101-CDx (Pixclara™) Granted FDA Fast Track Designation	16.04.
Telix Pharmaceuticals Limited Announces FDA Fast Track Designation for TLX101-CDx	16.04.
Telix Pharmaceuticals Limited completa la adquisición de ARTMS Inc.	11.04.
Telix Pharmaceuticals Limited completes the acquisition of ARTMS, Inc.	11.04.
Telix Pharmaceuticals Completes Acquisition of Canadian Firm ARTMS	11.04.
Telix Pharmaceuticals Limited completed the acquisition of ARTMS, INC.	11.04.
Telix Pharmaceuticals Completes Acquisition of IsoTherapeutics Group	09.04.
Telix Pharmaceuticals Limited completed the acquisition of IsoTherapeutics Group, LLC for $8.1 million.	09.04.
Telix Pharmaceuticals - World First Use of Lightpoint's SENSEI Drop-In Gamma Probe in Bladder Cancer Surgery Performed in Spain	27.03.
World First Use of Lightpoint's SENSEI® Drop-In Gamma Probe in Bladder Cancer Surgery Performed in Spain	26.03.
Telix Pharmaceuticals Limited Announces First Patient Dosed in Italian Named Patient ( Early Access) Program for TLX250-CDx Telix's Kidney Cancer Imaging Agent	25.03.
QDOSE Platform Partnership for Personalized Dosimetry in Radiopharmaceutical Therapy	19.03.
QDOSE® Platform Partnership for Personalized Dosimetry in Radiopharmaceutical Therapy	18.03.
Telix Pharmaceuticals Appoints Group COO; Shares Down 4%	12.03.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Telix Pharmaceuticals Limited

Aktien

A2H7JK

AU000000TLX2

TLX

Andere Sprachen

Filter